Key result
YC_GVI-1 vaccination confers 100% protection against the heterologous JS96_GI-19 strain in chickens.
The naturally attenuated YC_GVI-1 strain induces strong humoral immunity and provides complete protection against the heterologous JS96_GI-19 strain in chickens, offering potential for vaccine development.
Answers are grounded in this paper and cite their sources.
Supports attenuated YC_GVI-1 as IBV vaccine candidate; leaves open field efficacy and regulatory translation in poultry.
Infectious bronchitis virus (IBV) causes a highly contagious disease in chickens. The prevalence of GVI-1 is increasing; however, the genomic characteristics and antigenic properties of this genotype strain remain insufficiently characterized. In this study, the genome characteristics and antigenic properties of a naturally attenuated CK/CH/SC/YC_GVI-1-DK/LMB20210104 (abbreviated as YC_GVI-1) strain were systematically analyzed. YC_GVI-1 occupies a distinct phylogenetic lineage and shares a similarity of 98.2%, the highest nucleotide sequence homology, with the reference strain CK/CH/FJ/202005 (accession number: MW791835.1). This strain was likely originated through a genetic recombination event between two major parental strains, CK/CH/FJ/202005 and CK/CH/GX/HX (accession number: PP817796.1). However, its S protein harbors ten unique amino acid substitutions, compared to the same protein in the other two virulent strains in the same genotype. AlphaFold3-based structural prediction reveals that one of these substitutions, methionine 485 to valine substitution, may induce a conformational change in the adjacent phenylalanine residue at position 431, resulting in a shift in the local secondary structure from β-sheet to random coil. Characterization of its antigenicity showed that this strain induces a strong humoral immune response, with neutralizing antibody titers of 26.40 against homologous strain YC_GVI-1 and 24.00 against heterologous strain JS96_GI-19. Furthermore, vaccination of chickens with this strain conferred complete protection (100%) against JS96_GI-19. The findings provide novel insights into the molecular evolution and antigenicity of YC_GVI-1, offering key information for improving IBV surveillance and vaccine development.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2026) studied Infectious bronchitis virus (IBV). Vaccination with naturally attenuated YC_GVI-1 strain was evaluated on Protection against JS96_GI-19. Vaccination of chickens with the naturally attenuated YC_GVI-1 strain conferred complete protection against the heterologous JS96_GI-19 strain.
Synapse has enriched 10 related papers. Consider them for comparative context: